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ABSTRACT Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonates 
and denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-related 
events in patients with metastatic bone cancer and multiple myeloma. Available data suggest 
that 0–27.5% of individuals exposed to antiresorptive agents can develop ONJ.  There is 
increasing evidence that avoidance of surgical trauma and infection to the jawbones can 
minimize the risk of ONJ, but there are still a significant number of individuals who develop 
ONJ in the absence of these risk factors. Bone necrosis is almost irreversible and there is no 
definitive cure for ONJ with the exclusion, in certain cases, of surgical resection. However, 
most ONJ individuals are affected by advanced incurable cancer and are often managed 
with minimally invasive nonsurgical interventions in order to control jawbone infections 
and painful symptoms. This article summarizes current knowledge of ONJ epidemiology, 
manifestations, risk-reduction and therapeutic strategies. Further research is needed in 
order to determine individual predisposition to ONJ and clarify the effectiveness of available 
treatments. 
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Antiresorptive agents have revolutionized the treatment of cancer in individuals with bone metas-
tases and those with multiple myeloma as they can effectively prevent skeletal complications and 
relieve bone pain (Table 1) [1]. There is now overwhelming evidence that bisphosphonates (BPs) can 
reduce skeletal morbidity in multiple myeloma and solid tumors affecting bone by 30–50% [2]. 
Recent studies have shown that the new RANKL inhibitor denosumab can be even more effective 
than BPs in reducing the incidence of and delaying the time to skeletal-related events [3]. BPs are also 
useful in preventing cancer treatment-related bone loss in individuals with chemotherapy-related 
ovarian failure, and those who have been exposed to aromatase inhibitors and androgen deprivation 
therapy [4]. Further research is required to confirm the suggestion that some antiresorptive agents 
may also modify the course of the disease and disrupt the metastatic process, thereby reducing the 
risk of disease progression and prolonging disease-free survival, especially in early-stage cancers [2,4, 5].
Although adverse events related to antiresorptive therapy are usually considered to be infre-
quent and mild, osteonecrosis of the jaw (ONJ) is now established as a clinically significant, poten-
tially painful and debilitating condition that can significantly affect the quality of life of patients 
with cancer [6]. Of note, it is estimated that the magnitude of its negative effects is equivalent to 
other side effects associated with cancer treatment, which influences treatment decisions, possibly 
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reducing the potential benefit of antiresorptive 
agents [6]. Jaw osteo necrosis has been suggested 
to occur in 0–27% of metastatic bone cancer 
and myeloma patients receiving nitrogen- 
containing BP (N-BP) [7] and also denosumab, 
a novel anti-RANKL antiresorptive agent [8]. 
Furthermore, ONJ cases have been reported after 
antiangiogenic treatment, with and without BP 
therapy [9]. 
The aim of this article is to summarize current 
knowledge regarding ONJ associated with anti-
resorptive therapy in cancer patients and discuss 
future perspectives regarding prevention and 
management of this debilitating condition. It is 
beyond the scope of this work to determine the 
level of evidence of available literature as the vast 
majority of current data and procedures remain 
empirical and based upon expert opinion and 
experience-based decision-making. 
Definition
The first definition of ONJ was introduced by 
the American Association of Oral and Maxil-
lofacial Surgery (AAOMS) [10] and comprised 
the following criteria:
 ● Current or previous treatment with BPs;
 ● Exposed bone in the maxillofacial region that 
has persisted for more than 8 weeks and;
 ● No history of radiation therapy to the jaw.
This definition, which relies heavily upon 
the presence of clinically evident necrotic bone 
exposed through the oral mucosa or facial 
skin, has been adopted by the vast majority of 
clinical and epidemiological studies, and com-
monly used in clinical trials for case adjudi-
cation. However, several independent reports 
have recently highlighted that ONJ does not 
always present with oral mucosa fenestration 
and necrotic bone exposure [11–17].
The so-called ‘nonexposed variant of jaw 
osteonecrosis’, initially reported in 2008, is 
characterized by a number of other clinical 
features to the jaw that develop in the absence 
of frank bone exposure [11–14,18,19]. These 
include otherwise unexplained jawbone pain, 
fistula/sinus tract, loose teeth, swelling and, 
in advanced cases, pathological fracture of the 
mandible. Of note, diagnosis of nonexposed 
osteonecrosis is based on excluding common 
jawbone diseases, such as odontogenic infec-
tions and other bone disorders known to cause 
similar manifestations. It is estimated that the 
Table 1. Antiresorptive agents used in cancer and myeloma patients.
API Formulation Route Indication and schedule 
Alendronic acid 
(sodium salt)
Tab 70 mg
Tab 10 mg
p.o. Treatment of postmenopausal osteoporosis (70 mg/week)
Treatment of osteoporosis in men (70 mg/week)
Treatment and prevention of osteoporosis induced by glucocorticoids (70 mg/week)
Alendronic acid + 
cholecalciferol 
Tab 70 mg/5600 UI p.o. Treatment of postmenopausal osteoporosis in patients with unsupplemented vitamin D 
deficit (70 mg/week)
Ibandronic acid 
(monosodium salt 
monohydrate)
Tab 50 mg
Btl 6 mg/6 ml
p.o.
iv.
Prevention of SREs in breast cancer patients with bone metastases (50 mg/day p.o. or 6 mg 
every 3–4 weeks iv.)
Treatment of hypercalcemia of malignancy
Tab 150 mg
Btl 3 mg/3 ml
p.o.
iv.
Treatment of postmenopausal osteoporosis in patients at high risk of fracture 
(150 mg/4 weeks p.o. or 3 mg every 3 months iv.)
Neridronate acid 
(sodium salt)
Btl 25 mg/2 ml
Btl 100 mg/8 ml
iv./im.
iv.
Osteogenesis imperfecta (2 mg/kg/3 months)
Paget’s bone disease (different schedules)
Pamidronic acid 
(disodium salt)
Btl 15 mg/5 ml
Btl 30 mg/10 ml
Btl 60 mg/10 ml
Btl 90 mg/10 ml
iv. Prevention of SREs in breast cancer patients with bone metastases or MM with bone 
lesions (60–90 mg every 3–4 weeks)
Treatment of hypercalcemia of malignancy
Zoledronic acid 
(monohydrate)
Btl 4 mg/5 ml iv. Prevention of SREs in cancer patients with bone metastases or MM (4 mg every 3–4 weeks)
Treatment of hypercalcemia of malignancy
Btl 5 mg/100 ml iv. Treatment of osteoporosis in postmenopausal women, in men at increased risk of fracture, 
including those with a recent hip fracture from minor trauma (5 mg once per year)
Treatment of bone Paget’s disease
Denosumab Btl 120 mg sc. Prevention of SREs in cancer patients with bone metastases (120 mg every 4 weeks) 
Treatment of hypercalcemia of malignancy
Btl 60 mg sc. Osteoporosis (60 mg sc. every 6 months)
API: Active pharmaceutical ingredient; Btl: Bottle;  im. Intramuscular; iv.: Intravenous; MM: Multiple myeloma; p.o.: Orally; sc.: Subcutaneous; SRE: Skeletal-related event; Tab: Tablet.
Epidemiology, clinical manifestations, risk reduction & treatment strategies of jaw osteonecrosis REVIEW
future science group www.futuremedicine.com 259
nonexposed variant can represent up to a third 
of all ONJ cases [11]. 
The term ‘stage 0’ was first used by Mawardi 
et al. to gather suspected ONJ cases presenting 
with clinical and radiological signs of disease 
other than oral bone exposure [14]. Eventu-
ally, the AAOMS acknowledged the existence 
of these clinical manifestations and included 
the nonexposed variant within the ‘stage 0 
group’ of the revised staging system in 2009 
[20]. Nevertheless, their case definition was not 
modified accordingly and it remained focused 
upon the clinical evidence of long-standing 
bone exposure. This, therefore, continued to 
influence entry criteria and case adjudication 
in clinical studies, leading to a likely under-
estimate of ONJ incidence. This paradox was 
highlighted by several authors who called for an 
urgent change in case definition [16,17]. Lately, 
attention has been raised regarding the poten-
tial role of imaging for the diagnosis and staging 
of ONJ patients. A combination of clinical and 
radiological signs, albeit not specific for ONJ, 
may be more inclusive and representative of the 
bone disease process [21].
Within this perspective, a refined case defini-
tion and severity score system have recently been 
proposed, both of which are based on the radio-
logical extent of bone involvement rather than 
intraoral bone exposure alone [22]. Remarkably, 
in a recent document [23] the American Asso-
ciation of Maxillofacial Surgery also seemed to 
be more willing to accept the use of imaging 
techniques for ONJ detection and presurgical 
evaluation. 
Epidemiology
ONJ associated with antiresorptive agents is a 
relatively new disease. Strangely, ONJ was not 
detected in initial BP trials and the first cases 
were reported in 2003 [24–27]. The epidemiology 
of ONJ remains unclear due to inconsistency 
and limitations of available studies, including 
a lack of a specific ICD code, under-reporting 
in surveillance drug systems, a recent intro-
duction of preventive measures, case adjudi-
cation restricted to exposed ONJ, short-term 
observation and a lack of cumulative long-term 
incidence rates (Table 2) [11,28–48].
A recent review reports a wide-ranging ONJ 
incidence from 0 to 27.5%, relevant to indi-
viduals exposed to intravenous N-BP [7], with 
a mean incidence of 7%. The high variation in 
incidence figures is probably related to referral 
bias, as well as differences in study design and in 
the provision or risk-reduction dental strategies 
[7]. A recent meta-ana lysis reports the mean inci-
dence of ONJ associated with denosumab to be 
1.7% [49–52]. Interestingly, the studies reviewed 
in the meta-ana lysis reported a similar incidence 
of N-BP-associated ONJ, which is significantly 
less than previously reported; this may reflect 
the systematic adoption of risk-reduction dental 
strategies, but also differences in study design 
(e.g., observation time was in all cases less than 
5 years and therefore shorter that most previous 
BP studies). 
The oversuppression of osteoclast-mediated 
bone remodeling and consequent bone scle-
rosis and ischemia has been suggested to play 
a major pathogenetic role in ONJ, which was 
also confirmed by animal studies [53,54]. This 
would also explain the increased risk of ONJ 
associated with concomitant use of BP and anti-
angiogenic agents. A number of local factors 
have been consistently reported to increase the 
risk of ONJ development, including surgery to 
the jawbone and dental infection. It remains 
unclear however whether infection represents 
a primary event or simply a colonization of 
already necrotic ischemic bone. Overall, ONJ 
pathogenesis is not fully understood and the 
reason why only a subgroup of patients tak-
ing antiresorptive drugs develop ONJ remains 
unexplained. A detailed list of factors identified 
in the subgroup of patients developing ONJ is 
discussed below.
Clinical manifestations
Exposed ONJ, by definition, is characterized by 
the presence of clinically evident necrotic bone, 
which is exposed through the oral mucosa or 
facial skin, tending to affect the mandible 
more frequently than the maxilla [55]. Com-
mon associated manifestations include soft 
tissue swelling and erythema, pus discharge, 
fistula/sinus tracts, tooth loss, jaw deformity, 
pain and sensory disturbances. The dimension 
of exposed bone in ONJ can vary from a few 
millimetres to several centimetres. Of note, 
little is known regarding the true extension 
of necrotic bone surrounding the superficial 
exposed areas, as very few studies have reported 
data from radiographs, computed tomography 
(CT) or MRI scans [56]. It seems that the vast 
majority of patients present with localized bone 
disease, which often is painful and infected [55]. 
Yet, several patients seem to display clinical 
Future Oncol. (2014) 10(2) future science group260
REVIEW Campisi, Fedele, Fusco, Pizzo, Di Fede & Bedogni
manifestations of a more severe advanced 
form of ONJ; this includes an extension of 
necrosis and infection to the inferior border 
and ramus of the mandible, sinuses or zygoma 
in the maxilla, and it leads to severe intrac-
table pain, sinusitis, pathological fracture, and 
oral-antral/nasal communication [55]. 
Clinical manifestations of the nonexposed 
variant of ONJ include otherwise unexplained 
jawbone pain, fistula/sinus tract, swelling, loose 
teeth and pathological fractures [11–14,18,19]. 
Notably, these individuals have no apparent 
cause for these clinical signs and symptoms, 
and indeed the diagnosis of nonexposed ONJ 
is one of exclusion from other possible jawbone 
disorders (e.g., dental infection and metasta-
ses). It has been suggested that nonexposed 
ONJ can account for approximately a third of 
all ONJ cases [11], and that only half of the 
cases progress over time to develop frank bone 
exposure. 
The AAOMS has introduced a classifica-
tion/staging system of ONJ based on clinical 
manifestations, which they suggest should also 
guide treatment [20]. This has been criticized 
by several authors who have highlighted the 
need to incorporate all potential manifesta-
tions of ONJ, including the nonexposed vari-
ant, and add imaging as part of the staging 
classification/system (Table 3) [22].
Systemic risk factors
A number of the systemic risk factors have been 
associated with increased likelihood of ONJ 
Table 2. Epidemiology of osteonecrosis of the jaw.
Patient population Odds of ONJ (frequency/incidence/prevalence) Ref.
BRONJ in metastatic cancer and MM 
patients
Variable frequency (range: <1 to >20%; from case series and epidemiologic studies) 
Limitations: different cancer subsets, N-BP type and length of exposure and follow-up
Cumulative 2-year risk of ONJ lowers with oral preventive measures in cancer patients 
on monthly infusions of zoledronate
[28]
[30]
[111]
BRONJ in metastatic breast cancer 
patients 
Variable frequency (range: 1–8%); higher risk for zoledronate users than pamidronate [30,58,61]
BRONJ in nonmetastatic breast cancer 
patients (adjuvant setting)
17 adjudicated ONJ cases (1.1%) and 9 suspected cases among 1686 patients in the 
largest finalized study (AZURE) on zoledronic acid use
0.52% in all zoledronic acid studies (different schedules and follow-up)
[4]
[37]
Denosumab-related ONJ in metastatic 
breast cancer patients
2% (20 out of 1020) adjudicated ONJ cases (median on-study time: 17 months) in one 
large trial (vs 1.4% after zoledronic acid)
[51]
BRONJ in metastatic prostate cancer 
patients
Variable frequency (range: 3–20%); increased frequency (11 out of 55; 20%) in one 
experimental trial combining zoledronic acid and antiangiogenic agents
[38–40,58]
BRONJ in nonmetastatic prostate 
cancer patients (adjuvant setting)
3.5% (2 out of 58) ONJ cases after 5 zoledronic acid infusions (every 3 months for 1 year) [41]
Denosumab-related ONJ in metastatic 
prostate cancer patients
2% (22 out of 943) adjudicated ONJ cases (median on-study time: 12.2 months) in one 
large trial (vs 1% after zoledronic acid)
[43]
Denosumab-related ONJ in 
nonmetastatic prostate cancer patients 
(adjuvant setting)
5% (33 out of 720) adjudicated ONJ cases (median on-study time: 20 months) in one 
large trial
[44]
BRONJ in bone metastatic cancer 
different from breast and prostate
Large variations in case series
1.3% (11 out of 878) adjudicated ONJ cases (median on-study time: 7 months) in one 
large trial with zoledronic acid
[30]
[42]
Denosumab-related ONJ in bone 
metastatic cancer different from breast 
and prostate
1.1% (10 out of 878) adjudicated ONJ cases (median on-study time: 7 months) in one 
large trial with denosumab 
[42]
BRONJ in multiple myeloma patients Variable frequency (range: 0–51%) in case series and reviews (typically 6–16%)
Higher frequency with zoledronic acid than with pamidronate, especially at low doses
4% (35 out of 983) adjudicated ONJ cases after zoledronic acid vs 0.3% (3 out of 979) 
after chlodronate in one large randomized study
Lower incidence in zoledronic acid-treated patients with monthly infusions during the 
first year and then every 3 months
[45,46,58,65]
[47]
[35]
[48]
Denosumab-related ONJ in myeloma 
patients
Unknown (trials ongoing) –
BRONJ: Bisphosphonate-related osteonecrosis of the jaw; MM: Multiple myeloma; N-BP: Nitrogen-containing bisphosphonate; ONJ: Osteonecrosis of the jaw.
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development, including drug-related factors, 
genetic variants and comorbidities (Table 4) [57]:
 ● Administered drugs: in hematological and 
oncological patients, zoledronic acid (admin-
istered to the majority of ONJ patients but 
also the drug most commonly used, at least 
after 2002) seems to result in a statistically 
higher risk of ONJ [58–62] compared with 
pamidronate, and this is despite the absence 
of randomized studies. Insufficient data do not 
allow a definitive comparison with ibandro-
nate, even if the latter appears to be at lower 
risk [63]. Clodronate (a non-nitrogenous BP, 
mainly used in patients with myeloma) is asso-
ciated with a lower risk of ONJ in comparison 
with zoledronic acid [35], which is probably due 
to a different mechanism of action, as well as 
frequency of use.
 ● Administration route (intravenous vs oral): 
there is a higher risk for intravenous injection 
of N-BP but this factor may be closely related 
to their prevalent use in cancer patients 
(at signif icantly higher total doses and 
durations) [28,63,64].
 ● Total dose of administered N-BP (cumulative 
doses): available data indicate a higher risk of 
developing ONJ with an increase in total 
N-BP dose, which is intravenously adminis-
tered monthly to cancer and hematological 
patients, both for zoledronate and pamidro-
nate [58–60]. As previously reported, there are 
insufficient follow-up data for intravenous 
zoledronate and ibandronate in noncancer 
patients (administered every 3, 6 to 
12 months). Regarding cumulative doses and 
duration of treatment with oral BPs, the 
majority of cases of ONJ were observed in 
osteoporotic patients treated for years (usually 
more than 2–3 years), with an average of 
4.6 years, according to the review by Palaska 
et al. [65].
 ● Duration of treatment with intravenous N-BP: 
on average, ONJ patients were treated for lon-
ger periods than those without ONJ. The 
duration of intravenous treatment with N-BP 
is generally correlated with the total dose of 
drug administered, given the type of monthly 
administration, continuous and indefinite in 
time, recommended by major guidelines, at 
least until 2007 [60,66,67]. In a recent review of 
the literature [65], the mean/minimum time 
for the appearance of ONJ were 1.8 years and 
10 months, respectively, for zoledronate, and 
2.8 and 1.5 years, respectively, for pamidro-
nate, but cases of ONJ appearing after few 
N-BP infusions are occasionally reported 
(often after tooth extractions). However, more 
data are needed, after more recent recommen-
dations [68–70] and preliminary results of ran-
domized trials [71] have indicated the possibil-
ity of less prolonged BP treatment (1–2 years, 
with a subsequent tailoring of therapy). 
Finally, despite the lack of studies separately 
analyzing the survival time factor from the 
duration of treatment with BP, the increasing 
survival of cancer and hematological patients 
Table 3. Clinical and radiological osteonecrosis of the jaw staging system.
Stage ONJ type
Stage 1† Focal ONJ
Clinical signs and symptoms: bone exposure, sudden dental mobility, nonhealing postextraction socket, mucosal fistula, swelling, 
abscess formation, trismus and gross mandible deformity hypoesthesia/paraesthesia of the lips
CT signs: increased bone density limited to the alveolar bone region (trabecular thickening and focal osteosclerosis), with or 
without the following signs: markedly thickened and sclerotic lamina dura, persisting alveolar socket and cortical disruption
Stage 2‡ Diffuse ONJ
Clinical signs and symptoms: same as stage 1
CT signs: increased bone density extended to the basal bone (diffuse osteosclerosis), with or without the following signs: 
prominence of the inferior alveolar nerve canal, periosteal reaction, sinusitis, sequestra formation and oro-antral fistula
Stage 3 Complicated ONJ
Same as stage 2, with one or more of the following: 
Clinical signs and symptoms: extra-oral fistula, displaced mandibular stumps and nasal leakage of fluids
CT signs: osteosclerosis of adjacent bones (zygoma and hard palate), pathologic mandibular fracture and osteolysis extending to 
the sinus floor 
†Stage 1a: asymptomatic; stage 1b: symptomatic (pain and purulent discharge). 
‡Stage 2a: asymptomatic; stage 2b: symptomatic (pain and purulent discharge). 
CT: Computed tomography; ONJ: Osteonecrosis of the jaw. 
Data taken from [57].
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(time between diagnosis of advanced cancer 
and death) could prove to be [58,66,67,72,73] an 
additional risk factor responsible for a pro-
longed exposure to other (known and 
unknown) risk factors. 
 ● Concurrent treatment with a biological drug: 
recently, the combined use of latest-generation 
antiangiogenic agents (i.e., bevacizumab, suni-
tinib and sorafenib) and N-BP has been asso-
ciated with an increased risk of developing 
ONJ (Table 5) [9,28,62,74,75].
There is also emerging evidence of an 
increased incidence of ONJ in cancer patients 
treated with tyrosine-kinase inhibitors and bev-
acizumab [76–79]. On the contrary, conflicting 
data have been published regarding the role of 
thalidomide [80,81]:
 ● Individual genetic susceptibility to ONJ 
development has been investigated in a small 
number of genome-wide association and can-
didate gene studies [82–84]. The largest study 
performed so far (n = 94 ONJ cases) suggests 
that MHC class II polymorphisms may rep-
resent genetic risk factors related to the 
development of ONJ [85].
 ● Hypocalcemia, hyperparathyroidism and 
bone mineralization disorders: a single study 
demonstrated the possible contributing effect 
of secondary hyperparathyroidism after 
administering BP to developing ONJ [86]. 
Recently, a strong association between osteo-
malacia and ONJ has been identified [87], and 
the potential triggering effect of vitamin D 
deficiency on secondary hyperparathyroidism 
and bone mineralization defects has been 
already shown in animal models and is 
currently under investigation [88].
Other systemic risk factors for ONJ currently 
under investigation are reported in Table 4. 
Oral risk factors 
A general consensus exists that dentoalveolar 
surgery and simple dental extraction in particu-
lar are the most significant risk factors associ-
ated with ONJ in cancer patients taking anti-
resorptive drugs (Table 5) [89]. Dental implant 
placement is also considered a potential trigger 
for ONJ to occur in cancer patients, although 
the true risk has not yet been assessed [90]. 
Dental and periodontal infection significantly 
increases the risk of ONJ in cancer patients 
exposed to antiresorptive therapy [91–94]. 
Indeed, periodontal disease was diagnosed 
in 84% of cases in a large sample of patients 
with ONJ [89]. However, periodontal disease 
is commonly observed in the general popu-
lation in individuals >40 years of age, which 
may represent a confounding factor in assessing 
epidemiological association [95–98]. Also, early 
clinical stages of ONJ are known to include 
nonexposed alveolar bone necrosis that can 
mimic clinical and radiological manifestations 
Table 4. Drug-related and systemic risk 
factors of osteonecrosis of the jaw in the 
cancer population.
Risk factor Strength
Drug (BP)
Product (zoledronate vs others) +++
Route of administration (iv. vs oral) ++
Cumulative dosage +++
Duration of treatment +++
Underlying disease (for which treatment with 
N-BP is indicated)
Solid tumors ++
Multiple myeloma ++
Supportive care
Chemotherapy -/+
Steroids in cancer patients -/+
Antiangiogenic drugs 
(i.e., bevacizumab and sunitinib)
++
Thalidomide +/-
Erythropoietin stimulation factors +/-
Lifestyle
Smoking +/-
Alcohol -/+
Obesity +/-
Individual features
Sex +/-
Age +/-
Genetic factors +/-
Comorbidity
Diabetes +/-
Rheumatoid arthritis +
Hypocalcemia, hyperparathyroidism +
Vitamin D deficit, osteomalacia +
Renal dialysis +/-
Anemia +/-
-/+: Occasionally positive data unproven in larger studies; 
+: Positive data in some studies but still inconclusive; 
+/-: Positive and negative data, unlikely to be confirmed; 
++: Positive data in most studies; +++: Sound and consistent 
data; BP: Bisphosphonate; iv.: Intravenous; 
N-BP: Nitrogen-containing bisphosphonate. 
Reproduced with permission from [57].
Epidemiology, clinical manifestations, risk reduction & treatment strategies of jaw osteonecrosis REVIEW
future science group www.futuremedicine.com 263
of periodontitis (tooth mobility, bone loss, loss 
of attachment and pus discharge), which may 
lead to misdiagnosis and overestimation of the 
association between ONJ and periodontitis. 
Furthermore, a significant correlation has been 
documented between the use of removable den-
tures and the development of ONJ in a popula-
tion of metastatic cancer patients treated with 
high-dose intravenous N-BP [59,63]. Other oral 
triggers have been reported in the literature but 
lack definite validation (Table 6).
Natural history, long-term behavior 
& prognosis
Little is known regarding the natural history, 
long-term behavior and overall prognosis of 
ONJ associated with antiresorptive agents. Jaw 
osteonecrosis has been traditionally described 
as a chronic disorder with persisting, sometimes 
progressing, clinical manifestations with a poor 
response to curative therapeutic attempts [24,99]. 
There is currently a paucity of knowledge in the 
literature detailing the course of ONJ in the 
absence of therapeutic intervention (natural his-
tory). However, anecdotal evidence and clinical 
experience suggest that a proportion of patients 
suffer from an aggressive disease that progresses 
rapidly to cause severe pain with necrosis and 
infection of large areas of the jawbones whereas 
in other individuals ONJ may remain local-
ized and minimally symptomatic [100]. Several 
patients present with asymptomatic forms of 
exposed ONJ from the beginning, which exfo-
liate and tend to heal with stable mucosal cov-
erage, without further recurrences. These cases 
have been considered for a long time and are 
accordingly grouped as initial and localized 
forms of ONJ (AAOMS stage 1) based on the 
clinical signs and symptoms of disease. Recently, 
a multicenter retrospective study conducted in a 
large ONJ population (800 patients) and known 
as MISSION, proved that staging performed 
using AAOMS criteria, while pooling together 
patients with similar clinical findings, cannot 
adequately discriminate the extent of bone dis-
ease as determined by CT. In fact, nonspecific 
CT signs of ONJ are present for all AAOMS 
disease stages, which are almost indistinguish-
able, so that every stage contains patients with 
very different degrees of bone involvement [101]. 
It is generally agreed that interruption of 
antiresorptive therapy does not modify the 
natural history of the disease owing to the long 
half-life and persistence of these agents within 
the bone tissue [64]. Indeed there is no robust 
evidence showing remission of clinical mani-
festations (e.g., mucosal coverage of areas of 
previously exposed bone) and/or reduction in 
pain symptoms on N-BP withdrawal. However, 
it has been suggested that the natural history 
of ONJ associated with denosumab may differ 
from BP-related ONJ due to the shorter half-life 
of this agent, which may facilitate bone healing 
and symptom remission after removal of necrotic 
bone and suspension of therapy [102]. However, 
there are no studies at the moment supporting 
this hypothesis. 
More evidence, although not robust, is avail-
able regarding the long-term behavior of ONJ 
after or during therapy, as well as the prognosis 
Table 5. Main antiangiogenic drugs used in cancer and myeloma patients in combination with nitrogen-containing 
bisphosphonates, potentially increasing osteonecrosis of the jaw risk.
API Formulation Route Indication and schedule 
Bevacizumab Btl 400 mg
Btl 100 mg
iv. Metastatic breast cancer (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks); 
colorectal cancer (5 mg/kg or 10 mg/kg every 2 weeks); lung/ovarian cancer 
(7.5 mg/kg or 15 mg/kg every 3 weeks); renal cell cancer (10 mg/kg every 
2 weeks); glioblastoma (10 mg/kg every 2 weeks)
Sunitinib Tab 12.5 mg p.o. Renal cell cancer, GISTs and neuroendocrine tumors (50 mg/day for 4 weeks)
Sorafenib Tab 200 mg p.o. Renal cell cancer (800 mg/day)
Pazopanib Tab 200 mg
Tab 400 mg 
p.o. Renal cell cancer (200–800 mg/day)
Thalidomide Tab 50 mg p.o. Myeloma (400 mg/day for 6 weeks)
Lenalidomide Tab 5, 10, 15 and 25 mg p.o. Myeloma (tailored doses)
mTOR inhibitors
Everolimus Tab 5 and 10 mg p.o. Renal cell cancer, breast cancer (10 mg every day)
Temsirolimus Btl 30 mg iv. Renal cell cancer (25 mg every week) 
API: Active pharmaceutical ingredient; Btl: Bottle; GIST: Gastrointestinal stromal tumor;  iv.: Intravenous; p.o.: Orally; Tab: Tablet.
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of the overall disease. The terminology used so 
far to describe the long-term behavior and prog-
nosis of ONJ is unclear and confusing per se, 
which makes interpretation of available litera-
ture difficult. Defining the resolution of ONJ, 
healing, improvement and worsening varies 
among studies, and these factors remain incon-
sistent [49,103–106]. Some authors have adopted a 
more practical terminology and used complete 
mucosal coverage of a previously exposed jaw-
bone area as a surrogate of disease improvement, 
resolution or healing [107–109]. However, this is 
controversial as bone necrosis is an irreversible, 
ischemic process and complete mucosal cover-
age does not necessarily indicate that underlying 
necrotic bone has ‘healed’ [28]. Indeed, whereas 
some patients with ongoing necrosis but com-
plete mucosal coverage and no pain may only 
require monitoring (clinical examination and 
imaging), others may experience nonexposed 
disease progression, which may potentially lead 
to pathological fracture and require surgical 
treatment. Furthermore, very few studies have 
used pain as an independent outcome [109–111], 
although this may well be more relevant to 
patients than the presence of exposed bone. 
The variability and inconsistency of therapeu-
tic regimens in the literature are another factor 
limiting the understanding of the long-term 
behavior and prognosis of this disorder. Cases 
of ONJ of mild-to-moderate severity are often 
managed conservatively with antibiotics, local 
antimicrobials and the minimally invasive sur-
gical debridement of superficial necrotic bone 
spicules [28,64,112], whereas more severe cases are 
often addressed by resection of large portions 
of maxillofacial bone [20,105,111]. Comparison 
of these different patient groups has proven 
very difficult due to significant discrepancies 
in study objectives, outcome measures and risk 
factors. 
With respect to ONJ prognosis (e.g., pretreat-
ment vs post-treatment disease status), available 
studies report a rate of ‘resolution’, ‘healing’ or 
‘improvement’ (which indicate absence or dimen-
sional reduction of an area of exposed jawbone) 
ranging from 15 to 80% of affected individuals, 
with an average of 50% [103–105,107,110–115]. The 
remaining 50% of ONJ patients is thought to 
present persistent and/or progressive disease [104]. 
Those few studies reporting pain as an outcome 
describe the remission of painful symptoms 
in approximately 60–75% of patients [109,110]. 
These figures suggest that pain control can be 
achieved in the majority of patients, irrespective 
of the presence of exposed bone.
The long-term behavior of ONJ was stud-
ied in a small cohort of 30 patients by O’Ryan 
et al., who reported that osteonecrosis can have 
a recurrent and refractory course in approxi-
mately a third of cases, especially when it is 
triggered by dental extractions and associated 
with comorbidities [113]. Moretti et al. state that 
the course of ONJ is usually characterized by a 
progressive reduction in the dimension of bone 
exposure and painful symptoms in the major-
ity of affected individuals, irrespective of the 
therapeutic regimen [116].
Risk-reduction strategies & the safety of 
dental procedures
Risk-reduction strategies are suggested to repre-
sent an effective means of reducing the incidence 
of ONJ associated with antiresorptive agents in 
the cancer population [28,117,118]. In the absence of 
randomized controlled trials testing the efficacy 
of different treatments in patients at risk of ONJ 
development, the best level of evidence for risk-
reduction strategies comes from observational 
studies (type III evidence). Recently, the Joint 
Committee of the Italian Societies of Maxillo-
facial Surgery and Oral Pathology and Medicine 
launched a critical path ana lysis of the known 
risk-reduction strategies for ONJ, introducing a 
flow-chart of dental measures aimed at reducing 
the risk of ONJ in individuals exposed to/due to 
Table 6. Oral risk factors of antiresorptive 
drug-related osteonecrosis of the jaw in the 
cancer population.
Oral risk factors Strength
Dental implant surgery +++
Dental/periodontal infection ++
Removable dentures +++
Dentoalveolar surgery
Simple dental extraction +++
Regenerative bone procedures ++
Endodontic surgery ++
Periodontal surgery ++
Preimplant bone surgery +++
Anatomical conditions
Tori and exostosis +/-
Pronounced mylohyoid ridge +
+/-: Positive and negative data, unlikely to be confirmed; 
+: Positive data in some studies but still inconclusive; 
++: Positive data in most studies; +++: Sound and consistent 
data. 
Data taken from [57].
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start antiresorptive agents [57]. Despite different 
care professionals being involved in the design of 
these pathways, large gaps in knowledge persist 
among both physicians and dentists [119], as well 
as deficiencies in the information provided to the 
patient [120]. 
It is the responsibility of prescribing physi-
cians to provide cancer patients who are about 
to start therapy with BP or other antiresorptive 
drugs with adequate information regarding the 
risk of developing ONJ, and refer them for a 
thorough dental and oral examination prior 
to therapy commencement. Conversely, it is 
the responsibility of the dental care provider 
to implement preventive measures and inform 
patients about the need for continuing dental 
care during treatment with antiresorptive agents. 
Patients must be informed that a significant 
risk of ONJ occurrence remains despite the 
adoption of specific preventive protocols. This 
is because ONJ has been described to develop 
in absence of frank dental trauma or infec-
tion, and also because there are a number of 
minor factors that cannot be easily controlled 
(e.g., hard food trauma to areas of thin mucosa, 
including mylohyoid ridge and tori). Patients 
should also be told about the possible clinical 
manifestations of ONJ in order to promptly 
alert the oncologist/dental practitioner and 
anticipate a final diagnosis [120]. A rational, 
preventive approach should consider drug- and 
dental-related issues. The aim of prevention is 
to remove any possible dental and periodontal 
infection foci and to maintain patients’ oral 
health over time. Whether therapy with anti-
resorptive agents has already been commenced 
or not makes a clear difference in the adoption 
of specific preventive measures, in addition to 
the presence of dental and periodontal disease. 
Preventive dentistry may reduce the prevalence 
of ONJ in those receiving denosumab as it has 
in those receiving BPs [121]. In cases where the 
administration of N-BP or antiresorptive agents 
has been planned but not yet initiated, the oral 
cavity of the patient must be carefully checked 
clinically and should be imaged for any patho-
logical condition (e.g., tooth caries, periodontal 
diseases, pressure sores caused by incongruous 
removable prostheses and teeth with question-
able prognosis), and then treated according to 
standard dental practice. It is critical to delay the 
initiation of antiresorptive agents until a definite 
healing of the oral mucosa has been obtained 
[122,123].
In cases where the administration of anti-
resorptive agents has been already commenced, 
the oral cavity of the patient must be carefully 
inspected for dental and periodontal diseases 
and then treated according to specific protocols 
(Table 7). While several dental therapies can be 
performed in cancer patients undergoing anti-
resorptive agents without increasing the risk of 
ONJ, dental extractions and oral surgery should 
be always avoided where possible. Clearly dental 
extractions do not always trigger ONJ in patients 
exposed to antiresorptive agents, which shows 
how little we know regarding individual and 
personalized risk assessment. In the absence 
of better evidence, all patients exposed to anti-
resorptive medications should be advised to 
avoid surgical procedures to the jawbones where 
possible. In cases where dental surgical proce-
dures cannot be avoided, the use of minimally 
invasive surgery has been suggested to improve 
bone healing, which includes careful shaving of 
sharp edges of the extraction socket and tight 
primary soft tissue closure with mucoperiosteal 
flaps [100,124–126]. There remains, of course, cases 
where intravenous N-BP therapy needs to be ini-
tiated immediately and therefore risk-reduction 
dental strategies would have to be omitted [127]. 
Once started on antiresorptive regimens, can-
cer patients should be included in a protocol of 
dental and periodontal infection prevention and 
supportive periodontal therapy on a 4-month 
follow-up basis [96]. The use of ill-fitting dentures 
should be also investigated at each visit for the 
presence of oral mucosal injuries and the den-
tures relined accordingly. The positive correlation 
between the duration of exposure to BPs or anti-
resorptive agents and the risk of ONJ has been 
documented in the literature [24] and explains the 
need for apparently frequent recall visits. 
While the antiresorptive activity of deno-
sumab is reversible and time dependent, the 
effects of N-BPs and zoledronate in particular 
are long lasting, even after a single infusion. 
Indeed, it has been shown that these molecules 
inhibit bone remodeling for several years after 
incorporation into bone [128]. For these rea-
sons, overall agreement exists that elective oral 
surgery and periodontal surgery, including 
bone grafts and insertion of dental implants, 
are contra indicated in multiple myeloma and 
metastatic cancer patients who are on or have 
been exposed to N-BP infusions. A temporary 
cessation of antiresorptive therapy (‘drug holi-
day’) has been suggested among risk-reduction 
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strategies. Although it is possible that the heal-
ing potential of bone and the oral mucosa could 
progressively improve following cessation of 
antiresorptive drugs [129], there remains no 
study demonstrating significant benefits from 
drug holidays in this setting. Some authors have 
suggested that temporary withdrawal of N-BP 
therapy may allow better soft tissue healing [130] 
following tooth extraction [124] and also surgi-
cal resection [111] by reducing drug accumula-
tion into the operated site. However, there is 
no robust evidence to support this theory. The 
choice to discontinue N-BP should always be 
taken together with the oncologist and then 
maintained until completion of the healing 
process [124]. 
A rational, preventive approach must also 
take into account dental-related issues and spe-
cifically the feasibility of elective and therapeutic 
procedures. 
Two possible scenarios exist: first, a cancer 
patient with maintained oral health, for whom 
only preventive dental/periodontal measures 
or elective procedures are necessary and, sec-
ond, a cancer patient with existing dental, peri-
odontal or perimplant disease and/or mucosal 
lesions of a traumatic nature, for whom suitable 
therapeutic strategies are needed. 
In general, each elective nonsurgical pro-
cedure (restorative dentistry, prosthodontics, 
periodontics, endodontics and orthodontics), 
including professional hygiene, can be safely 
carried out, based on the treatment protocols 
normally used for the general population. How-
ever, elective surgical procedures (e.g., implant 
surgery, preimplant bone surgery and periodon-
tal surgery) need to be carefully evaluated and 
should be avoided when the administration 
of BP/antiresorptive agents has been already 
commenced. 
Medical management of ONJ
Managing ONJ has proven to be difficult and it 
remains a major challenge for clinicians. 
Robust evidence from well-designed clinical 
trials is scarce, and the most available treatment 
recommendations reflect expert opinions and 
are, therefore, characterized by a low level of evi-
dence [7,20,30,131,132]. In addition, such recommen-
dations have been developed for use in BP-related 
ONJs exclusively. At present, little information 
is accessible on the treatment of ONJ caused by 
denosumab. Denosumab-related osteonecrosis 
theoretically differs from bisphosphonate-related 
osteonecrosis of the jaw in that the drug-induced 
suppression of bone turnover is transient and 
Table 7. Dental treatment warnings for cancer patients at risk of antiresorptive drug-related osteonecrosis of the jaw.
Dental treatments Malignancies
Before antiresorptive therapy During & after antiresorptive therapy
Dentoalveolar surgery and preimplant 
bone surgery
Indicated: simple tooth extraction†
Contraindicated: preimplant bone surgery
Necessary await until complete wound 
healing (4–6 weeks) before start of 
antiresorptive therapy 
Indicated: surgical tooth extraction‡
Contraindicated: preimplant bone surgery
Advisable: 1-month temporary withdrawal of 
antiresorptive drug (in agreement with prescribers) to 
facilitate wound healing (4–6 weeks)
Dental implant surgery Contraindicated Contraindicated
Cosmetic and restorative dentistry Indicated Indicated
Endodontic treatment Indicated Indicated
Orthodontic treatment Possible Possible 
Periodontology: oral hygiene and 
nonsurgical treatments
Indicated Indicated (every 4 months) 
Periodontal/endodontic surgery Indicated‡§ Indicated‡§
Advisable: 1-month temporary withdrawal of 
antiresorptive drug (in agreement with prescribers) to 
facilitate wound healing (4–6 weeks)
Fixed dentures Possible Possible (maintenance of biologic width)
Removable dentures Possible Possible (frequent denture reline advisable)
Dental procedures are classified as follows: indicated (none or low risk, or, in turn, when the benefit derived from the treatment far exceeds the risk of osteonecrosis of the jaw); 
possible: low risk without specific contraindications, but the benefits of the treatment have to be outweighed case by case; contraindicated: the risk of osteonecrosis of the jaw 
associated with the procedure is high and the benefits for the patient are insubstantial. 
†If antiresorptive therapy cannot be further delayed, dental surgery is advisable. 
‡Warrant airtight closure of the surgical site with the use of mucoperiosteal flaps. 
§Only if aimed at treating significant ongoing inflammatory-infective processes not otherwise curable.  
Reproduced with permission from [57].
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the disease process may have more favorable 
outcomes once the drug has been waived, thus 
requiring less invasive management [52]. How-
ever, in the absence of a specific treatment pro-
tocol for denosumab-associated ONJ, it seems 
reasonable to adopt those developed for the treat-
ment of bisphosphonate-related osteonecrosis of 
the jaw. 
The nonsurgical management of ONJ is 
aimed at improving the stage of the disease and 
avoiding its progression. It includes the use of 
antimicrobial mouth rinses (0.2% chlorhexi-
dine digluconate), local disinfection/cleaning 
of exposed bone and fistula, pain control, and 
the administration of antibiotics and nutri-
tional support when required. In the presence 
of exposed bone, superficial debridement may be 
useful to reduce sharp edges and relieve soft tis-
sue irritation [20,23,110,116,131–134]. Broad-spectrum 
antibiotics (amoxicillin/clavulanic acid, ampicil-
lin/sulbactam, metronidazole or clindamycin) 
are the first-line drugs to be used in combina-
tion although the use of other antibiotics (such 
as erythromycin, ciprofloxacin and doxycycline) 
has also been documented in the literature 
[20,132,134]. Systemic antibiotics are recommended 
in the presence of overt infection (e.g., suppura-
tion and abscess formation) and local inflam-
mation, with or without pain [20]. Ten days to a 
3-week course with oral antibiotic therapy has 
been suggested, but there is little research avail-
able that indicates the most efficient drug and 
course duration.
In refractory and severe cases of ONJ, intra-
venous antibiotic therapy may be required [20]. 
Patients with nonspecific clinical findings and 
symptoms (e.g., intraoral sinus tract or jaw 
pain), but in the absence of clinically exposed 
bone (AAOMS stage 0), may also benefit from 
systemic antibiotic therapy, in association with 
chronic pain medication when indicated [20]. 
The medical treatment of ONJ may also be 
indicated for patients with a poor prognosis of 
the underlying neoplastic disease, who would 
not benefit from extensive radical surgery [20,134].
It has been suggested that a reduction in 
the intraoral bacterial load plays an important 
role in ONJ management as it may minimize 
the risk of exposed bone infection and disease 
progression. ONJ patients should be carefully 
educated towards maintenance of good oral 
hygiene, routine dental examinations and pre-
ventive dental care. This is particularly relevant 
in cancer patients who may suffer from a number 
of adverse side effects to the oral cavity asso-
ciated with the use of antineoplastic therapy, 
including oral mucositis, xerostomia and oral 
graft-versus-host disease [135]. These side effects, 
particularly in cases of ONJ, significantly affect 
patients’ quality of life and cause chronic pain, 
eating discomfort, aesthetic concerns and 
decreased life satisfaction [6]. Optimal oral 
hygiene requires appropriate motivation, ade-
quate tools (toothbrush, dental floss and tape, 
interproximal brushes, woodsticks, single-tufted 
brushes, a tongue cleaner and disclosing solution 
to identify dental plaque) and professional oral 
hygiene instructions. Preventive care includes 
the removal of supra- and sub-gingival plaque 
and calculus (scaling and root planning).
In addition to infection and pain control, a 
number of therapeutic strategies have been sug-
gested to be of potential benefit to patients with 
ONJ. Systemic low-dose recombinant human 
parathyroid hormone (i.e., teriparatide) has been 
reported to induce a resolution of clinical signs 
and the symptoms of ONJ in a noncancer set-
ting. However, the evidence is weak due to the 
uncontrolled design and small size of relevant 
studies [131,136–139]. Hyperbaric oxygen therapy 
was suggested to increase the effectiveness of 
medical and/or surgical treatment of ONJ [111,140] 
but concerns remain regarding its cost–effective-
ness, the impact on quality of life and the overall 
clinical benefit [141,142]. Finally, limited evidence 
is available to support the use of low-intensity 
laser and medical ozone therapy [103,143,144].
It is widely agreed that suspension of anti-
resorptive therapy would provide little benefit, 
if any, to ONJ prognosis due to the long half-life 
of N-BP and because the risk of a malignant 
disease progression largely exceeds the potential 
benefits in most cases [20,26,28,70,145–153]. In the 
absence of conclusive evidence, it seems sensible 
not to withdraw N-BP therapy in individuals 
who have developed ONJ [20,26,28,70,145–153]. 
Denosumab has a significantly shorter half-life 
than N-BPs and its effects of bone turnover are 
more rapidly reversible; therefore, ONJ related 
to denosumab may be less likely to recur once 
the necrotic bone has exfoliated or has been sur-
gically removed and the antiresorptive treatment 
has been suspended [20,26,28,70,145–153]. 
Surgical management of ONJ
The benefits of surgical management of ONJ have 
been extensively debated in the available litera-
ture. The surgical resection of necrotic jawbone 
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has been traditionally considered palliative rather 
than curative, as it has been offered mainly to 
patients with advanced disease not responding to 
medical treatment [7,154,155]. There is now enough 
evidence to suggest that nonsurgical treatment 
often fails to provide positive outcomes in ONJ 
patients with advanced disease [7,112], whereas rad-
ical surgery seems to offer more predictable and 
curative results [7,20,27,64,66,131,156–164]. However, 
the surgical treatment of early-stage ONJ remains 
controversial [34,103,159–161,163,165,166]. 
Kuhl et al. found that the negative results of 
previous studies were probably biased by the fact 
that surgery is often performed in patients with 
poor health and extensive necrosis [7]. Indeed, 
when medical and surgical treatments were com-
pared in terms of clinical healing and resolution 
of pain, surgery has been demonstrated to per-
form better for all disease stages [7,105,106]. On the 
basis of this increasing evidence, the AAOMS has 
recently highlighted the role of resective surgery 
[23] in restoring form and/or function as opposed 
to controlling symptoms and delaying the pro-
gression of the disease. Standardized terminology 
has been adopted in the literature to categorize 
resective surgical procedures for ONJ patients 
(i.e., marginal and segmental resection) [111,158], 
whereas there is less clarity regarding conservative 
surgical treatments. 
The Joint Committee of the Italian Societies of 
Maxillofacial Surgery and of Oral Pathology and 
Medicine has recently proposed a classification 
of surgical procedures based on their invasive-
ness and recommended their allocation to ONJ 
patients on the basis of the radiological extent of 
disease, as seen on CT (Table 8) [22 ,132]. Conser-
vative surgical treatments (i.e., debridement or 
bone curettage, and sequestrectomy) differ from 
surgical resection in that the removal and curet-
tage of necrotic bone is performed without the 
intention of including a margin of normal sur-
rounding bone [158,167]. When using conservative 
surgical treatments, the boundary between nor-
mal and diseased bone is usually based on the 
intraoperative identification of areas of vascular-
ized ‘bleeding’ bone at the margins of necrotic 
avascular ischemic bone [157,161,163,168]. However, 
this approach is not advisable in patients with 
advanced bone disease as it has been associated 
with a high recurrence rate of ONJ [56]. Of note, 
methods to aid identification of healthy bone 
margins are currently being investigated, includ-
ing tetracycline bone labeling [169–171] and more 
detailed preoperative CT-based surgical planning 
[111]. Clinical judgment alone often underesti-
mates the amount of diseased bone at the time 
of surgery, thus leaving in place diseased, albeit 
vascularized, bone, that may later become evi-
dent as ‘new’ foci of ONJ, even at distant sites. In 
this way, new foci may actually be ‘recurrent’ foci 
and this possibility has to be taken into account 
when interpreting the available studies. New 
foci of ONJ should always be proved by imag-
ing, showing the absence of a connection with 
the operated site.
Although some authors advocate direct vas-
cular impairment of the oral mucosa caused by 
N-BP accumulation in the pathogenesis of ONJ 
[130,172], it is well understood that the oral mucosa 
can be safely spared during ONJ surgery and the 
same can also be used to obtain stable mucosal 
coverage of the operated site, once the necrotic 
bone has been fully removed [111,158,173,174]. 
Some reports suggest the use of less invasive 
instruments, such as low-level laser therapy 
and piezoelectric surgery, which may minimize 
Table 8. Management of drug-related osteonecrosis of the jaw in metastatic cancer and multiple myeloma patients.
SICMF-SIPMO Surgical therapy†‡§¶ Medical therapy#
Stage 1 (focal ONJ) Dentoalveolar surgery: curettage and bone sequestrectomy; 
marginal resection for recurrent disease 
Perioperative topical disinfection (clorexidine 0.2%)
iv. perioperative antibiotic therapy (7–14 days long)
Oral disinfectants
Systemic antibiotic therapy (7–14 day long) 
(to be done monthly or in case of recurrent pain and 
suppuration)
Accessories: biostimulation (ozone or laser therapy); 
hyperbaric oxygen therapy
Aims: symptomatic (palliation); spontaneous 
sequestration of necrotic bone; remission
Stage 2 (diffuse 
ONJ) and stage 3 
(complicated ONJ)
Segmental resection (bone reconstruction if indicated) 
iv. perioperative antibiotic therapy (7–14 days long)
Perioperative topical disinfection (clorexidine 0.2%)
†Stable mucosal coverage of the operated site should be always achieved irrespective of the surgical technique adopted.  
‡Accessories: use of piezoelectric or laser-assisted surgery to minimize ischemic damage to bone. 
§1-month postoperative withdrawal of antiresorptive agent is advisable to reduce its excessive accumulation at the surgical site that could hamper the healing process.  
¶Postoperative clinical follow-up at 1, 3, 6 and 12 months. CT scans at 6 and 12 months after surgery. 
#Suitable for early-stage disease, systemically compromised patients for whom surgical therapy is contraindicated, or in case of patient’s refusal of surgery.  
iv.: Intravenous; ONJ: Osteonecrosis of the jaw; SICMF: Italian Societies of Maxillofacial Surgery; SIMPO: Italian Societies of Oral Pathology and Medicine. 
Data taken from [57].
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vascular damage to the bone and promote a faster 
and pain-free healing of soft and bone tissues [175]. 
However, there remains little robust evidence to 
support their superiority to traditional bone-
cutting equipment. Similarly, the real benefit 
of combining bone resection with autologous 
platelet-rich plasma remains unclear [176].
One controversial aspect of the aforemen-
tioned surgical literature relies on the definition 
of outcomes and related time points. The cur-
rent definition of healing indicates the clinical 
evidence of stable oral mucosal coverage and it 
has been adopted by the vast majority of surgical 
studies [158,161]; however, mucosal coverage does 
not necessarily reflect the absence of underlying 
necrotic bone. Likewise, it is still uncertain how 
long the oral mucosa should remain intact to 
confirm stable healing. Despite several authors 
believing a 6-month clinical follow-up to be 
sufficient to confirm a definite cure [167,171,177], 
there is increasing evidence that ONJ may recur 
1 year or more after the completion of surgery 
[111,158,161,163]. In addition, the radiological signs 
of ONJ recurrence may manifest themselves well 
before the onset of any clinical sign or symptom. 
It would, therefore, seem sensible to monitor ONJ 
patients for at least 1 year and perform CT imag-
ing at 6-month intervals in order to evaluate the 
long-term outcomes of surgical treatment. 
Perioperative, antibiotic therapy and topical 
disinfection with chlorhexidine mouthwash, 
until complete soft tissue healing is achieved, 
are recommended in the vast majority of surgi-
cal protocols. The potential benefit of temporary 
postoperative interruption of N-BP has been sug-
gested but supporting evidence remains incon-
clusive [111]. It seems reasonable to speculate that 
in the future the combination of medical treat-
ments (i.e., pain control, local disinfection and 
antibiotics) and surgical therapy could become 
the leading strategy where complete and success-
ful healing is achievable. Single-modality medical 
EXECUTIVE SUMMARY
 ● Osteonecrosis of the jaw (ONJ) represents a clinically significant, potentially painful and debilitating condition that can 
significantly affect the quality of life of cancer patients. Its occurrence is related to current or previous treatment with 
antiresorptive agents (bisphosphonates [BPs] and denosumab). 
 ● The incidence of BP-related ONJ widely ranged from 0 to 27.5% (mean: 7%) due to inconsistency and limitations of 
available studies. A meta-ana lysis of few recent studies reports a mean incidence of 1.7% for ONJ associated with 
denosumab, with no statistical differences when directly compared with zoledronic acid.
 ● The oversuppression of osteoclast-mediated bone remodeling and consequent bone sclerosis and ischemia has been 
suggested to play a major pathogenetic role in ONJ.
 ● Exposed ONJ is characterized by the presence of clinically evident necrotic bone, affecting the mandible more 
frequently than the maxilla. Common associated manifestations include soft tissue swelling and erythema, pus 
discharge, fistula/sinus tracts, tooth loss, jaw deformity, pain and sensory disturbances.
 ● ONJ does not always present with oral mucosa fenestration and necrotic bone exposure, but it may occur as otherwise 
unexplained jawbone pain, fistula/sinus tract, swelling, loose teeth and pathological fractures.
 ● Dentoalveolar surgery and simple dental extraction are the most significant risk factors associated with ONJ.
 ● The natural history of ONJ associated with denosumab may differ from BP-related ONJ due to the shorter half-life of 
this agent.
 ● Risk-reduction strategies are suggested to represent an effective way of reducing the incidence of ONJ. These 
strategies include the removal of any possible dental and periodontal infection foci, and the maintenance of patients’ 
oral health over time.
 ● The nonsurgical management of ONJ is aimed at improving the stage of the disease and avoiding its progression. 
It includes the use of antimicrobial mouth rinses (0.2% chlorhexidine digluconate), local disinfection/cleaning of 
exposed bone and fistula, pain control and the administration of antibiotics and nutritional support when required. 
In the presence of exposed bone, superficial debridement may be useful to reduce sharp edges and relieve soft tissue 
irritation.
 ● The nonsurgical treatment often fails to provide positive outcomes in ONJ patients with advanced disease, whereas 
radical surgery seems to offer more predictable and curative results. However, the surgical treatment of early-stage 
ONJ remains controversial.
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